Results for tag: "Methylmalonic Acidemia Drug"

Methylmalonic Acidemia (MMA) is a rare, inherited metabolic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. This enzyme is responsible for breaking down certain proteins and fats in the body. Without it, the body cannot properly process these proteins and fats, leading to a buildup of methylmalonic acid in the blood. Symptoms of MMA include vomiting, lethargy, poor feeding, and developmental delays. Treatment for MMA includes dietary modifications, vitamin B12 supplementation, and enzyme replacement therapy. The Methylmalonic Acidemia Drug market is a subset of the larger Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat MMA, such as enzyme replacement therapy, vitamin B12 supplementation, and dietary modifications. These drugs are used to reduce the buildup of methylmalonic acid in the blood and to improve the patient's quality of life. Some companies in the Methylmalonic Acidemia Drug market include Pfizer, Sanofi, Merck, and Novartis. Show Less Read more